appendix
form
part
origin
submiss
peer
review
post
suppli
author
supplement
goyal
v
grimwood
k
byrn
ca
et
al
amoxicillinclavulan
versu
azithromycin
respiratori
exacerb
children
bronchiectasi
multicentr
doubleblind
noninferior
randomis
control
trial
lancet
publish
onlin
sept
http
dx
longterm
macrolid
use
data
variou
adult
paediatr
randomis
control
trial
longterm
macrolid
bronchiectasi
show
macrolid
significantli
reduc
exacerb
frequenc
subgroup
children
studi
receiv
longterm
macrolid
antibiot
therefor
apriori
plan
subgroup
analysi
exclud
children
take
macrolid
antibiot
subgroup
analysi
includ
statist
analysi
plan
approv
data
safeti
monitor
committe
bronchiectasi
exacerb
studi
children
take
longterm
antibiot
baselin
receiv
cotrimoxazol
remain
take
one
macrolid
baselin
children
identifi
receiv
longterm
macrolid
antibiot
randomis
begin
exacerb
children
exclud
analys
primari
secondari
outcom
repeat
remain
children
supplement
figur
use
similar
statist
method
describ
main
manuscript
particip
randomis
amoxicillinclavulan
studi
arm
take
longterm
macrolid
return
baselin
state
compar
azithromycin
arm
also
receiv
antibiot
longterm
risk
differ
rd
resolut
azithromycin
compar
amoxicillinclavulan
group
perprotocol
pp
popul
confid
interv
ci
therebi
fall
within
apriori
calcul
noninferior
margin
supplement
figur
reaffirm
intentiontotreat
itt
analysi
ci
median
timetoresolut
exacerb
also
shorter
ie
better
amoxicillinclavulan
group
compar
azithromycin
vs
pp
well
itt
analys
differ
median
timetoth
next
exacerb
two
group
supplement
tabl
signific
betweengroup
differ
alter
parent
coughspecif
qualityoflif
score
inflammatori
marker
spirometri
paramet
children
data
avail
either
pp
itt
analys
supplement
tabl
similarli
azithromycin
resist
nasopharyng
staphylococcu
aureu
isol
cultur
children
pair
ns
avail
similar
group
note
though
aureu
isol
test
children
receiv
longterm
macrolid
antibiot
regardless
intervent
group
resist
azithromycin
remain
resist
supplement
tabl
posthoc
subgroup
analys
restrict
itt
undertaken
base
presenc
absenc
viru
begin
exacerb
primari
proport
children
whose
exacerb
resolv
within
treatment
period
three
secondari
outcom
chang
pcqol
length
exacerb
day
timetoth
next
exacerb
day
among
children
viru
detect
begin
exacerb
resolut
rate
amoxicillinclavulan
group
compar
receiv
azithromycin
rd
ci
fall
outsid
priori
defin
noninferior
margin
presenc
detect
viru
primari
outcom
result
also
outsid
noninferior
margin
resolut
rate
amoxicillinclavulan
azithromycin
respect
rd
ci
main
secondari
outcom
present
supplement
tabl
among
children
respiratori
viru
identifi
start
exacerb
total
group
found
receiv
azithromycin
significantli
longer
durat
symptom
compar
amoxicillinclavulan
group
howev
differ
group
larger
median
differ
compar
overal
cohort
median
differ
also
undertook
posthoc
subgroup
analys
base
age
primari
outcom
three
secondari
outcom
pcqol
length
exacerb
timetonext
exacerb
day
among
children
age
resolut
rate
amoxicillinclavulan
azithromycin
respect
rd
ci
outsid
noninferior
margin
acut
exacerb
resolv
children
age
amoxicillinclavulan
group
azithromycin
group
rd
ci
main
secondari
outcom
present
supplement
tabl
children
age
receiv
azithromycin
took
significantli
longer
resolv
treat
amoxicillinclavulan
versu
respect
signific
differ
group
chang
pcqol
score
found
irrespect
detect
viru
begin
exacerb
age
child
supplement
tabl
supplementari
tabl
figur
supplement
figur
repres
kaplan
meier
curv
median
timetonext
exacerb
day
azithromycin
compar
amoxicillinclavulan
present
tabl
main
manuscript
continu
data
present
mean
sd
supplement
interest
reader
aid
research
might
includ
data
futur
metaanalys
mean
sd
analys
supplement
tabl
comparison
clinic
characterist
two
treatment
group
begin
exacerb
present
supplement
tabl
interest
reader
futur
metaanalys
comparison
advers
symptom
two
group
present
supplement
tabl
data
present
mean
standard
deviat
proport
express
percentag
longterm
antibiot
use
children
cotrimoxazol
amoxicillinclavulan
arm
azithromycin
arm
abbrevi
crp
creactiv
protein
fev
forc
expiratori
volum
onesecond
percent
pcqol
parent
coughspecif
qualityoflif
wbc
white
blood
cell
count
atyp
pathogen
data
present
mean
standard
deviat
proport
express
percentag
except
day
onset
symptom
start
studi
medic
crp
median
th
th
percentil
children
seen
studi
doctor
treatment
exacerb
provid
complet
inform
includ
nasal
swab
sampl
abl
perform
spirometri
pneumonia
chlamydial
pneumonia
abbrevi
crp
creactiv
protein
ent
ear
nose
throat
fev
forc
expiratori
volum
onesecond
percent
pcqol
parent
coughspecif
qualiti
life
wbc
white
blood
cell
count
tabl
clinic
characterist
begin
exacerb
